Navigation Links
Insmed Incorporated Provides Regulatory Update
Date:10/10/2011

derstanding of the FDA's requests and their implications, we will provide a further update to the market."

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with high unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, results of operations, the status and the results of preclinical studies and clinical trials and preclinical and clinical data described herein, the timing of responses to information and data requests from FDA, the development of our products, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of FDA and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Insmed to Host Third Quarter 2010 Conference Call
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
11. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader ... at the Bank of America Merrill Lynch 2015 Health Care ... Vegas, Nevada on Wednesday, May 13, at 8 ... the presentation can be accessed via Zimmer,s Investor Relations website ... replay following the conference. About the Company Founded ...
(Date:5/6/2015)... YORK , May 6, 2015  The fairness ... or the "Company") by Alexion Pharmaceuticals, Inc. ("Alexion") is ... shareholder rights law firm, for possible breaches of fiduciary ... of Directors of GEVA for agreeing to sell the ... announced a definitive agreement for Alexion to acquire GEVA ...
(Date:5/6/2015)... 2015 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China, today announced its unaudited ... First Quarter 2015 Financial Highlights ... increased by 25.0% to $70.4 million from $56.3 million ... profit increased by 18.9% to $45.9 million from $38.6 ...
Breaking Medicine Technology:WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2China Biologic Reports Financial Results for the First Quarter of 2015 2China Biologic Reports Financial Results for the First Quarter of 2015 3China Biologic Reports Financial Results for the First Quarter of 2015 4China Biologic Reports Financial Results for the First Quarter of 2015 5China Biologic Reports Financial Results for the First Quarter of 2015 6China Biologic Reports Financial Results for the First Quarter of 2015 7China Biologic Reports Financial Results for the First Quarter of 2015 8China Biologic Reports Financial Results for the First Quarter of 2015 9China Biologic Reports Financial Results for the First Quarter of 2015 10China Biologic Reports Financial Results for the First Quarter of 2015 11China Biologic Reports Financial Results for the First Quarter of 2015 12China Biologic Reports Financial Results for the First Quarter of 2015 13China Biologic Reports Financial Results for the First Quarter of 2015 14China Biologic Reports Financial Results for the First Quarter of 2015 15China Biologic Reports Financial Results for the First Quarter of 2015 16China Biologic Reports Financial Results for the First Quarter of 2015 17China Biologic Reports Financial Results for the First Quarter of 2015 18
... many injections, in two pivotal Phase 3 trials, ... of sustained virologic response comparable to Pegasys (peginterferon ... comparable rates of serious and/or severe adverse events ... alfa-2a -- Submission of global marketing applications planned ...
... for the treatment of type 2 diabetesHAYWARD, Calif., April ... of patient accrual to a phase 1b clinical study ... study is being conducted at multiple centers in the ... with type 2 diabetes for a period of 4 ...
Cached Medicine Technology:Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3
(Date:5/6/2015)... (PRWEB) May 06, 2015 As ... the HIMSS EMR Adoption Model, the hospital looked ... patient engagement and automate processes. The leadership team ... paper-driven to electronic workflows, patient registration still required ... of consents. With HIMSS Stage 7 attestation fast ...
(Date:5/6/2015)... May 06, 2015 Corporate Executives ... of MEBC, an Alliance Award for excellence in ... FOCUS 2015, JDA’s annual user conference which brought ... and wholesale distribution sectors. This award recognizes MEBC, ... receiving services that advance their supply chain performance ...
(Date:5/6/2015)... The Beryl Institute announces the publication of ... (PXJ), an international, open access, peer-reviewed journal focused on ... experience. The second volume of PXJ supports the goal ... the voices engaged and provides the space for listening, ... The Beryl Institute, Volume 2, Issue 1 includes ...
(Date:5/6/2015)... Marketing Maven announces a ... sanitation and hygiene nonprofit by GuideStar’s Philanthropedia. , “WaterAid ... and it brings our agency great joy to work ... “The ongoing relationship between WaterAid and Marketing ... learn about and support the nonprofit as they aim ...
(Date:5/6/2015)... 06, 2015 Wolters Kluwer , ... and students, announced today that in a survey of ... use of the clinical decision support resource improves the ... of 2014, UpToDate users in more than 170 countries ... month, on average. In Germany alone, 95% of all ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3
... Dining Out For Life ... A night of food ... Every year since 1991, ActionAIDS has shown their ... and their philanthropy have made a very real difference ... with HIV and AIDS. ActionAIDS recognizes those individuals with ...
... The managing director of Publication CONNEXION, a CONNEXION ... the 45th Annual Drug Information Association (DIA) Meeting, ... a talk entitled "Effective Publication Practices" (Abstract number ... pharmaceutical industry five-day summit uniting professionals from all ...
... Reform should start with "evidence-based reimbursement", structuring physician ... benefit, which would improve quality and reduce the ... two cardiologists and published in Circulation: Cardiovascular ... For example, some 500,000 U.S. patients suffering from ...
... from UC San Diego just moved closer to ... from "proliferation mode" to "specialization mode." This computational ... bioengineering department could lead to new ideas for ... published in Nature Genetics , could also ...
... YDNT ) today announced that it will broadcast its ... conference call on Tuesday, April 28, 2009 at 11:00 a.m. Central ... available through InterCall at http://tinyurl.com/ydnt1QTR09 . ... available through the Company,s website, www.ydnt.com .For those ...
... and Women,s Hospital (BWH) and the Harvard-MIT Division ... way to deliver cancer drugs directly to tumors by ... pathway and deliver a higher concentration of medication to ... April 20, in an early online edition of the ...
Cached Medicine News:Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 2Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 3Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 4Health News:Health-care reform should start with paying evidence-based financial incentives to doctors 2Health News:How cells change gears: New insights published in Nature Genetics 2Health News:How cells change gears: New insights published in Nature Genetics 3Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 4
... to block tear drainage through the canaliculus, synthetic ... eye symptoms:, Indicated for use in the ... eye components of various ocular surface diseases, May ... eye related complications and to enhance the retention ...
... Inserted into the punctal opening to block ... provide long-term relief of dry eye symptoms, ... of its own natural tears:, Low-profile ... Flexibility of cap design facilitates easy removal ...
... The distinctive low profile dome head combined ... patient comfort. The pointed nose design simplifies ... shelf firmly secures plug making dislocation less ... and eliminates premature plug release. SOFT PLUG ...
... Flow Controllers may be used ... too much. The tapered shaft ... vector force, keeping it snugly ... it can be monitored. Designed ...
Medicine Products: